-
Archives of Internal Medicine May 2005Contrast-induced nephropathy (CIN) is an important cause of declines in kidney function and is related to greater morbidity, health care costs, and mortality. Adenosine... (Meta-Analysis)
Meta-Analysis Review
BACKGROUND
Contrast-induced nephropathy (CIN) is an important cause of declines in kidney function and is related to greater morbidity, health care costs, and mortality. Adenosine has been proposed to contribute to the pathophysiological process of CIN. We performed a systematic review and meta-analysis of theophylline, an adenosine antagonist, for the prevention of CIN.
DATA SOURCES
Studies were identified in all languages by search of MEDLINE (1966 through November 2003), EMBASE (1980 through week 44 [November] of 2003), and the Cochrane Controlled Clinical Trials Register (1996 through November 2003) databases and selected conference proceedings.
STUDY SELECTION
We searched for randomized controlled trials comparing theophylline vs control in patients receiving radiocontrast media for angiography or computed tomography.
DATA EXTRACTION
Our primary outcome measures were the risk of CIN, the difference in serum creatinine levels between theophylline and control groups at 48 hours and need for dialysis.
DATA SYNTHESIS
Nine randomized controlled trials involving 585 patients were identified and included for analysis. Theophylline protocols and definitions of CIN varied across studies. There was evidence of heterogeneity of results across trials (Q = 9.77; P = .08); therefore, pooled values require cautious interpretation. The overall pooled odds ratio (OR) using a conservative random-effects model was 0.40 (95% confidence interval [CI], 0.14 to 1.16; P = .09) indicating a trend toward reduction in the incidence of CIN with theophylline use. The pooled estimate for the difference in 48-hour serum creatinine levels between the theophylline and control groups was -0.17 mg/dL (95% CI, -0.28 to -0.06 mg/dL) (-15.2 micromol/L [95% CI, -24.6 to -5.7 micromol/L]) (P = .002), indicating that theophylline may be protective in CIN. The incidence of CIN requiring dialysis was uncommon and reported in only 1 case.
CONCLUSIONS
Theophylline may reduce the incidence of CIN with an efficacy that is perhaps comparable to that reported in studies of N-acetylcysteine. However, findings are inconsistent across studies. A large, well-designed trial that incorporates the evaluation of clinically relevant outcomes is required to more adequately assess the role for theophylline in CIN prevention.
Topics: Angiography; Contrast Media; Humans; Incidence; Kidney Diseases; Randomized Controlled Trials as Topic; Regression Analysis; Theophylline; Tomography, X-Ray Computed; Vasodilator Agents
PubMed: 15911721
DOI: 10.1001/archinte.165.10.1087 -
International Journal of Epidemiology Feb 2002Elevated concentrations of homocyst(e)ine are thought to increase the risk of vascular diseases including coronary heart disease and cerebrovascular disease. (Review)
Review
BACKGROUND
Elevated concentrations of homocyst(e)ine are thought to increase the risk of vascular diseases including coronary heart disease and cerebrovascular disease.
METHODS
We searched MEDLINE (1966-1999), EMBASE (1974-1999), SciSearch (1974- 1999), and Dissertation Abstracts (1999) for articles and theses about homocyst(e)ine concentration and coronary heart disease and cerebrovascular disease.
RESULTS
We included 57 publications (3 cohort studies, 12 nested case-control studies, 42 case-control studies) that reported results on 5518 people with coronary heart disease (11,068 control subjects) and 1817 people with cerebrovascular disease (4787 control subjects) in our analysis. For coronary heart disease, the summary odds ratios (OR) for a 5-micromol/l increase in homocyst(e)ine concentration were 1.06 (95% CI : 0.99-1.13) for 2 publications of cohort studies, 1.23 (95% CI : 1.07-1.41) for 10 publications of nested case-control studies, and 1.70 (95% CI : 1.50-1.93) for 26 publications of case-control studies. For cerebrovascular disease, the summary OR for a 5-micromol/l increase in homocyst(e)ine concentration were 1.10 (95% CI : 0.94-1.28) for 2 publications of cohort studies, 1.58 (95% CI : 1.35-1.85) for 5 publications of nested case-control studies, and 2.16 (95% CI : 1.65-2.82) for 17 publications of case-control studies.
CONCLUSIONS
Prospective studies offer weaker support than case-control studies for an association between homocyst(e)ine concentration and cardiovascular disease. Although other lines of evidence support a role for homocyst(e)ine in the pathogenesis of cardiovascular disease, more information from prospective epidemiological studies or clinical trials is needed to clarify this role.
Topics: Cardiovascular Diseases; Case-Control Studies; Cohort Studies; Confounding Factors, Epidemiologic; Coronary Disease; Homocysteine; Humans; Risk Factors
PubMed: 11914295
DOI: 10.1093/ije/31.1.59 -
Journal of Dairy Science Jan 2009Soils in many regions of the world have a low Se content. Consequently, forages and crops grown on these soils may provide inadequate dietary Se for humans and grazing... (Meta-Analysis)
Meta-Analysis Review
Soils in many regions of the world have a low Se content. Consequently, forages and crops grown on these soils may provide inadequate dietary Se for humans and grazing animals. Selenium supplementation has been used to enhance Se status and milk Se concentration, but results conflict. Milk Se concentration appears to be a useful indicator of animal and herd Se status, and reflects the responsiveness to supplementation. A systematic review and meta-analysis were carried out to summarize all available scientific evidence for the effect of oral Se supplementation on milk Se concentration in cattle. The literature search was based on electronic and nonelectronic databases. Fixed- and random-effects models of meta-analysis were used, and a meta-regression was carried out to evaluate heterogeneity among studies. Random-effects meta-analysis was performed on 42 studies published between 1977 and 2007. Oral Se supplementation resulted in an average increase in milk Se content of 0.16 (95% confidence interval: 0.117, 0.207) micromol/L, with a significant heterogeneity among studies. Weak publication bias was evident, but it did not change the average effect. The continent where the study was performed, Se source, Se dose, and the interaction between source and dose explained 71% of the between-study variance. On average, American cows supplemented with Se yeast (e.g., 6 mg/h per day) had greater milk Se concentrations (approximately 0.37 micromol/L) 75 d after the beginning of supplementation when compared with those supplemented with inorganic forms of Se. This information provides a basis for tailoring daily animal requirements and for enhancing the Se intake of consumers of dairy products.
Topics: Animals; Cattle; Dietary Supplements; Female; Milk; Publication Bias; Regression Analysis; Selenium
PubMed: 19109290
DOI: 10.3168/jds.2008-1545 -
Archives of Pediatrics & Adolescent... Nov 2009To compare available nomograms in the literature defining trends in bilirubin levels across populations with different risk factor profiles and to study a mathematical... (Review)
Review
OBJECTIVES
To compare available nomograms in the literature defining trends in bilirubin levels across populations with different risk factor profiles and to study a mathematical bilirubin kinetics model describing the natural course of jaundice and the bilirubin rate of rise needed to cross percentile curves.
DATA SOURCES
We searched PubMed for publications between March 1999 and March 2009 that created transcutaneous nomograms. We performed the same search among abstracts presented in the past 2 years at meetings of the Pediatric Academic Societies or the European Society for Paediatric Research.
STUDY SELECTION
Inclusion criteria were gestational age of at least 35 weeks among study subjects, the use of an electronic transcutaneous bilirubinometer, and creation of a nomogram based on hour-specific bilirubin values. Four articles met the selection criteria.
DATA EXTRACTION
Jaundice risk factors were analyzed, and raw data were analyzed using nonlinear regression to describe trends in bilirubin levels and kinetics. The bilirubin exaggerated rate of rise needed to cross percentile curves was calculated.
DATA SYNTHESIS
Significant differences in bilirubin values exist across populations, and there is substantial variability in rates of rise. Hispanic neonates demonstrate higher rates of rise and later plateaus. Bilirubin rates of rise tend to plateau and become null (equilibrium between bilirubin production and elimination) at about 96 hours of life. Rates of rise needed to cross percentile curves decrease over time but are lower (approximately 0.11 mg/dL/h [to convert bilirubin level to micromoles per liter, multiply by 17.104]) in the first 48 hours of life than previously thought.
CONCLUSIONS
Transcutaneous bilirubin levels plateau and then decrease after about 96 hours of life in healthy neonates, with some differences across populations. A bilirubin rate of rise higher than in the previous period implies that bilirubin production exceeds elimination and indicates high risk for subsequent hyperbilirubinemia in neonates.
Topics: Bilirubin; Humans; Hyperbilirubinemia, Neonatal; Infant, Newborn; Nomograms; Racial Groups; Skin; Time Factors
PubMed: 19884597
DOI: 10.1001/archpediatrics.2009.187 -
The Cochrane Database of Systematic... Oct 2006Double volume exchange transfusion is commonly used in newborns with severe jaundice in order to prevent kernicterus and other toxicity related to hyperbilirubinemia.... (Review)
Review
BACKGROUND
Double volume exchange transfusion is commonly used in newborns with severe jaundice in order to prevent kernicterus and other toxicity related to hyperbilirubinemia. Most commonly, exchange transfusions are used in infants with rhesus hemolytic disease.
OBJECTIVES
To compare the effectiveness of single volume exchange transfusion (SVET) with that of double volume exchange transfusion (DVET) in producing survival without disability and reducing bilirubin levels in newborn infants with severe jaundice.
SEARCH STRATEGY
MEDLINE, EMBASE (Excerpta Medica online), The Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library), SCISEARCH (Science Citation Index), Reference lists from the articles identified in the search of the databases, and from review articles were searched through March 2006. Personal communication with experts in the field was used to identify unpublished data.
SELECTION CRITERIA
All Randomised and quasi randomised control trials comparing single volume and double volume exchange transfusions in jaundiced newborn infants were included.
DATA COLLECTION AND ANALYSIS
Safety and efficacy of single and double volume exchange compared with regards to long term neurodevelopment, reduction in bilirubin levels and other complications during exchange transfusion. Data was evaluated separately with regards to the cause of jaundice. Relative risk (RR) and weighted mean difference (WMD) were calculated for dichotomous and continuous variables respectively. 95% confidence intervals were used and a fixed effects model was assumed.
MAIN RESULTS
Only one study fulfilled the criteria (Amato 1988). 20 full term babies requiring exchange transfusion for hemolytic jaundice due to ABO incompatibility were randomly allocated to receive single or double volume exchange transfusion. Base line characteristics of both groups were similar with regards to birth weight 3260 (SD 390) g vs. 3350 SD (410) g, gestational age 39 (SD 1) week vs. 40 (SD 0.8) week, immediate pre exchange bilirubin level 199 (SD 33) micromol/L vs. 216 (SD 55) micromol/L. Both groups were treated equally apart from the volume of blood used for exchange transfusion. Total bilirubin levels immediately after exchange transfusion were not significantly different in either group. No long term neurodevelopmental outcome was examined in this study.
AUTHORS' CONCLUSIONS
There was insufficient evidence to support or refute the use of single volume exchange transfusion as opposed to double volume exchange transfusion in jaundiced newborns. A change from the current practice of double volume exchange transfusions for severe jaundice in newborns infant, cannot be recommended on current evidence.
Topics: Bilirubin; Blood Group Incompatibility; Exchange Transfusion, Whole Blood; Humans; Infant, Newborn; Jaundice, Neonatal
PubMed: 17054210
DOI: 10.1002/14651858.CD004592.pub2 -
Annals of Internal Medicine Nov 2009Intravenous sodium bicarbonate has been proposed to reduce the risk for contrast-induced nephropathy (CIN). (Meta-Analysis)
Meta-Analysis Review
BACKGROUND
Intravenous sodium bicarbonate has been proposed to reduce the risk for contrast-induced nephropathy (CIN).
PURPOSE
To determine the effect of sodium bicarbonate on the risk for CIN.
DATA SOURCES
MEDLINE, PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials from 1950 to December 2008; conference proceedings; and ClinicalTrials.gov, without language restriction.
STUDY SELECTION
Randomized, controlled trials of intravenous sodium bicarbonate that prespecified the outcome of CIN as a 25% increase in baseline serum creatinine level or an absolute increase of 44 micromol/L (0.5 mg/dL) after radiocontrast administration.
DATA EXTRACTION
Using standardized protocols, 2 reviewers serially abstracted data for each study.
DATA SYNTHESIS
23 published and unpublished trials with information on 3563 patients and 396 CIN events were included. The pooled relative risk was 0.62 (95% CI, 0.45 to 0.86), with evidence of significant heterogeneity across studies (I(2) = 49.1%; P = 0.004). Some heterogeneity was due to the difference in the estimates between published and unpublished studies: relative risk, 0.43 (CI, 0.25 to 0.75) versus 0.78 (CI, 0.52 to 1.17), respectively. Meta-regression showed that small, poor-quality studies that assessed outcomes soon after radiocontrast administration were more likely to suggest benefit (P < 0.05 for all). No clear effects of treatment on the risk for dialysis, heart failure, and total mortality were identified.
LIMITATION
Power to assess clinical end points was limited.
CONCLUSION
The effectiveness of sodium bicarbonate treatment to prevent CIN in high-risk patients remains uncertain. Earlier reports probably overestimated the magnitude of any benefit, whereas larger, more recent trials have had neutral results. Large multicenter trials are required to clarify whether sodium bicarbonate has value for prevention of CIN before routine use can be recommended.
PRIMARY FUNDING SOURCE
None.
Topics: Acetylcysteine; Contrast Media; Heart Failure; Humans; Injections, Intravenous; Kidney Diseases; Mortality; Renal Dialysis; Risk; Sodium Bicarbonate
PubMed: 19884624
DOI: 10.7326/0003-4819-151-9-200911030-00008 -
BJOG : An International Journal of... Apr 2006Pre-eclampsia is one of the largest causes of maternal and fetal mortality and morbidity. Hyperuricemia is often associated with pre-eclampsia. (Review)
Review
BACKGROUND
Pre-eclampsia is one of the largest causes of maternal and fetal mortality and morbidity. Hyperuricemia is often associated with pre-eclampsia.
OBJECTIVE
To determine the accuracy with which serum uric acid predicts maternal and fetal complications in women with pre-eclampsia.
STUDY DESIGN
Systematic quantitative review of test accuracy studies.
SEARCH STRATEGY
We conducted electronic searches in MEDLINE (1951-2004), EMBASE (1980-2004), the Cochrane Library (2004:4) and the MEDION database to identify relevant articles. A hand-search of selected specialist journals and reference lists of articles obtained was then carried out. There were no language restrictions for any of these searches.
SELECTION CRITERIA
Two reviewers independently selected the articles in which the accuracy of serum uric acid was evaluated to predict maternal and fetal complications of pre-eclampsia.
DATA COLLECTION AND ANALYSIS
Data were extracted on study characteristics, quality and accuracy to construct 2 x 2 tables with maternal and fetal complications as reference standard. Summary likelihood ratios for positive (LR+) and negative LR(-) test results are generated for various threshold levels of uric acid.
MAIN RESULTS
There were 18 primary articles that met the selection criteria, including a total of 3913 women and forty-one 2 x 2 tables. In women with pre-eclampsia, a positive test result of uric acid greater than or equal to a 350-micromol/l threshold predicted eclampsia with a pooled likelihood ratio (LR) of 2.1 (95% CI 1.4-3.5), while a negative test result had a pooled LR of 0.38 (95% CI 0.18-0.81). For severe hypertension as the outcome measure, the LRs were 1.7 (95% CI 1.3-2.2) and 0.49 (95% CI 0.38-0.64) for positive and negative test results, respectively, and for caesarean section the LRs were 2.4 (95% CI 1.3-4.7) and 0.39 (95% CI 0.20-0.76). For stillbirths and neonatal deaths the respective LRs were 1.5 (95% CI 0.91-2.6) and 0.51 (95% CI 0.20-1.3). For the prediction of small-for-gestational-age fetus, the pooled LRs were 1.3 (95% CI 1.1-1.7) and 0.60 (95% CI 0.43-0.83) for positive and negative results, respectively. AUTHOR'S CONCLUSION: Serum uric acid is a poor predictor of maternal and fetal complications in women with pre-eclampsia.
Topics: Biomarkers; Cesarean Section; Female; Fetal Growth Retardation; HELLP Syndrome; Humans; Hypertension, Pregnancy-Induced; Pre-Eclampsia; Predictive Value of Tests; Pregnancy; Pregnancy Outcome; Prenatal Diagnosis; Sensitivity and Specificity; Stillbirth; Uric Acid
PubMed: 16553648
DOI: 10.1111/j.1471-0528.2006.00908.x -
BMJ (Clinical Research Ed.) May 2004To assess the effects of non-absorbable disaccharides (lactulose and lactitol) in patients with hepatic encephalopathy. (Comparative Study)
Comparative Study Review
OBJECTIVE
To assess the effects of non-absorbable disaccharides (lactulose and lactitol) in patients with hepatic encephalopathy.
DATA SOURCES
Cochrane Hepato-Biliary Group controlled trials register, Cochrane Library, Medline, and Embase until March 2003; reference lists of relevant articles; authors and pharmaceutical companies.
REVIEW METHODS
Randomised trials that compared non-absorbable disaccharides with placebo, no intervention, or antibiotics for hepatic encephalopathy were included. The primary outcome measures were no improvement of hepatic encephalopathy and all cause mortality.
RESULTS
22 trials were included. Compared with placebo or no intervention, non-absorbable disaccharides seemed to reduce the risk of no improvement in patients with hepatic encephalopathy (relative risk 0.62, 95% confidence interval 0.46 to 0.84, six trials). However, high quality trials found no significant effect (0.92, 0.42 to 2.04, two trials). Compared with placebo or no intervention, non-absorbable disaccharides had no significant effect on mortality (0.41, 0.02 to 8.68, four trials). Non-absorbable disaccharides were inferior to antibiotics in reducing the risk of no improvement (1.24, 1.02 to 1.50, 10 trials) and lowering blood ammonia concentration (weighted mean difference 2.35 micromol/l, 0.06 micromol/l to 13.45 micromol/l, 10 trials). There was no significant difference in mortality (0.90, 0.48 to 1.67, five trials).
CONCLUSIONS
There is insufficient evidence to support or refute the use of non-absorbable disaccharides for hepatic encephalopathy. Antibiotics were superior to non-absorbable disaccharides in improving hepatic encephalopathy, but it is unclear whether this difference is clinically important. Non-absorbable disaccharides should not serve as comparator in randomised trials on hepatic encephalopathy.
Topics: Anti-Infective Agents; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Randomized Controlled Trials as Topic; Sugar Alcohols; Treatment Outcome
PubMed: 15054035
DOI: 10.1136/bmj.38048.506134.EE -
The Cochrane Database of Systematic... Oct 2006Terlipressin may reverse some of the circulatory changes associated with hepatorenal syndrome. (Meta-Analysis)
Meta-Analysis Review
BACKGROUND
Terlipressin may reverse some of the circulatory changes associated with hepatorenal syndrome.
OBJECTIVES
To assess the beneficial and harmful effects of terlipressin for hepatorenal syndrome.
SEARCH STRATEGY
Electronic searches in The Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Renal Group Register, the Cochrane Central Register of Controlled Trials in The Cochrane Library, MEDLINE, and EMBASE were combined with scanning of bibliographies and conference proceedings, and correspondence with experts and pharmaceutical companies. Last search update was July 2006.
SELECTION CRITERIA
Randomised clinical trials were included irrespective of dose or treatment duration. Included patients had type 1 or type 2 hepatorenal syndrome. Co-interventions were allowed if administered equally to both treatment and control groups.
DATA COLLECTION AND ANALYSIS
Data were retrieved from trial reports and correspondence with the authors of included trials. Mortality was the primary outcome. Meta-analyses were performed to calculate risk differences (RD) for binary outcomes and weighted mean differences (WMD) for continuous outcomes. Both were presented with 95% confidence intervals (CI). Due to the limited number of trials, no subgroup analyses were performed.
MAIN RESULTS
The initial searches identified 645 potentially relevant references. Six randomised trials were eligible for inclusion. Three trials are still ongoing. Three trials with a total of 51 patients assessed terlipressin 1 mg bid for 2 to 15 days. Co-interventions included albumin, fresh frozen plasma, and cimetidine 800 mg daily. One trial reported adequate bias control assessed by randomisation and blinding. All trials reported mortality. Terlipressin reduced mortality rates by 34% (RD -0.34, 95% CI -0.56 to -0.12). The control group mortality rate was 65%. Terlipressin improved renal function assessed by creatinine clearance (WMD 21 ml/min, 95% CI 17 to 26), serum creatinine (WMD -219 micromol/l, 95% CI -244 to -194), and urine output (WMD 707 ml/day, 95% CI -212 to 1625). Adverse events included headache, abdominal pain, cardiac arrhythmia, and hypertension.
AUTHORS' CONCLUSIONS
Additional evidence on terlipressin for hepatorenal syndrome is needed before reliable treatment recommendations can be made. The dose and duration of therapy, and the influence of co-interventions remain to be established.
Topics: Hepatorenal Syndrome; Humans; Lypressin; Randomized Controlled Trials as Topic; Terlipressin; Vasoconstrictor Agents
PubMed: 17054242
DOI: 10.1002/14651858.CD005162.pub2 -
The Cochrane Database of Systematic... Apr 2006Target of rapamycin inhibitors (TOR-I) (sirolimus, everolimus) are immunosuppressive agents with a novel mode of action but an uncertain clinical role. (Meta-Analysis)
Meta-Analysis Review
BACKGROUND
Target of rapamycin inhibitors (TOR-I) (sirolimus, everolimus) are immunosuppressive agents with a novel mode of action but an uncertain clinical role.
OBJECTIVES
To investigate the benefits and harms of immunosuppressive regimens containing TOR-I when compared to other regimens as initial therapy for kidney transplant recipients.
SEARCH STRATEGY
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (in The Cochrane Library, issue 2, 2005), MEDLINE (1966-June 2005), EMBASE (1980-June 2005), the specialised register of the Cochrane Renal Group (June 2005)., and contacted authors and pharmaceutical companies to identify relevant studies.
SELECTION CRITERIA
All randomised controlled trials (RCTs) and quasi-RCTs where drug regimens containing TOR-I were compared to alternative drug regimens in the immediate post-transplant period were included, without age restriction, dosage or language of report.
DATA COLLECTION AND ANALYSIS
Two reviewers independently assessed trials for eligibility and quality, and extracted data. Results are expressed as relative risk (RR) or weight mean difference (MD) with 95% confidence intervals (CI).
MAIN RESULTS
Thirty three trials (142 reports) were included (sirolimus (27), everolimus (5), head-to-head (1)). When TOR-I replaced CNI there was no difference in acute rejection, but serum creatinine was lower (MD -18.31 micromol/L, -30.96 to -5.67), and bone marrow more suppressed (leucopenia: RR 2.02 1.12 to 3.66; thrombocytopenia: RR 6.97 2.97 to 16.36; anaemia: RR 1.67, 1.27 to 2.20). When TOR-I replaced antimetabolites, acute rejection (RR 0.84, 0.71 to 0.99) and cytomegalovirus infection (CMV) (RR 0.49; 0.37 to 0.65) were reduced, but hypercholesterolaemia was increased (RR 1.65, 1.32 to 2.06). For low versus high-dose TOR-I, with equal CNI dose, rejection was increased (RR 1.23, 1.06 to 1.43) but calculated GFR higher (MD 4.27 mL/min, 1.12 to 7.41), and for low-dose TOR-I/standard-dose CNI versus higher-dose TOR-I/reduced CNI, acute rejection (RR 0.67, 0.52 to 0.88) and calculated GFR (MD -9.46 mL/min, -12.16 to -6.76) were reduced. There was no significant difference in mortality, graft loss or malignancy risk for TOR-I in any comparison.
AUTHORS' CONCLUSIONS
TOR-I have been evaluated in four different primary immunosuppressive algorithms; as replacement for CNI and for antimetabolites, in combination with CNI at low and high dose and with variable dose of CNI. Generally, surrogate endpoints for graft survival favour TOR-I (lower risk of acute rejection and higher GFR) and surrogate endpoints for patient outcomes are worsened by TOR-I (bone marrow suppression, lipid disturbance). Long-term hard-endpoint data from methodologically robust RCTs are still needed.
Topics: Everolimus; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Kidney Transplantation; Randomized Controlled Trials as Topic; Sirolimus
PubMed: 16625599
DOI: 10.1002/14651858.CD004290.pub2